INCY: Summary for Incyte Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 6:59am EST - Canadian Markets open in 2 hours and 31 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Incyte Corporation (INCY)

On Nov 24: 7.72 USD 0.00 (0.00%)

MORE ON INCY

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Incyte Corporation (NGM:INCY) Delayed quote data

Last Trade:	7.72 USD
Trade Time:	Nov 24
Change:	0.00 (0.00%)
Prev Close:	7.72
Open:	N/A
Bid:	8.41 x 300
Ask:	11.00 x 1000
1y Target Est:	10.57

Day's Range:	N/A - N/A
52wk Range:	1.96 - 8.32
Volume:	0
Avg Vol (3m):	2,926,230
Market Cap:	915.13M
P/E (ttm):	N/A
EPS (ttm):	-1.76
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add INCY to Portfolio

Download Data

HEADLINES

•	UPDATE - Novartis strikes licensing deal with Incyte
	at Reuters (Wed 6:20am)

•	European Factors -- Shares set to open higher, data eyed
	at Reuters (Wed 2:48am)

•	Incyte to license 2 hematology drugs to Novartis
	at MarketWatch (Wed 2:28am)

•	Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs
	Business Wire (Wed 1:15am)

•	10 Stocks Shaking the Market
	at Motley Fool (Tue 11:50am)

•	INCYTE CORP Financials
	EDGAR Online Financials (Wed, Nov 11)

•	Blood Cancer Meeting Abstracts Released: BioBuzz
	at TheStreet.com (Tue, Nov 10)

•	Incyte Beats Estimates Marginally
	Zacks.com (Sun, Nov 8)

•	New Star Analyst Rankings for Incyte Corporation
	StarMine (Sun, Nov 8)

•	Incyte Corporation Q3 2009 Earnings Call Transcript
	at Seeking Alpha (Thu, Nov 5)

•	Incyte 3Q loss narrows on lower costs
	AP (Thu, Nov 5)

More Headlines for INCY...

ANALYST

EPS Est (next year) (Dec-09) :	-1.62
EPS Est (in 2 years) (Dec-10) :	-1.38
Avg Rec (current)*:	1.6
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.

Full Company Profile

Add to Portfolio

Email to a Friend

•